Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

ConditionMalignant Tumour

Trial statusRecruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age18-90

SponsorFirst Affiliated Hospital of Fujian Medical University

About this trial

As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

68Ga-dPNE
Drug
Intravenous injection of 68Ga-dPNE. 68Ga-dPNE PET/CT will be used to detect tumors.
18F-FDG
Drug
Intravenous injection of 18F-FDG.18F-FDG PET/CT will be used to detect tumors.

Treatment groups

30 Participants

are divided into 2 treatment groups

Group A: 68Ga-dPNE PET/CTExperimental treatment 1 intervention

Group B: 18F-FDG PET/CTExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

SUV of tumors

Compare the SUV of tumors between 68Ga-dPNE PET/CT and 18F-FDG PET/CT.

Time frame

Through study completion, an average of 3 months

Secondary outcomes

Diagnostic value

Sensitivity and specificity of 68Ga-dPNE in patients with various types of cancer and compare it with 18F-FDG PET/CT.

Time frame

Through study completion, an average of 3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

First Affiliated Hospital of Fujian Medical University

Lead sponsor

Source ClinicalTrials.gov

Apply now